Bernasconi-Bisio, Pineda-Lucena and colleagues established an integrative SdAb platform for CAR-T cell development addressing limitations of a conventional ScFv-based CAR against CD33 for AML targeting. Here, CD33 is linked to acute myeloid leukemia.